Ultime notizie per Genmab (NASDAQ:GMAB) Azioni

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Outperform and raises the price target from $69 to $89.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Moelis, Raises Price Target to $89

JP Morgan analyst Andrew Steinerman reinstates UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Underweight and announces $175 price target.

Initiation

JP Morgan Reinstates Underweight on UniFirst, Announces $175 Price Target

180 Degree Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURN#NASDAQ">TURN</a>) ("180 Degree Capital") today noted the filing of the definitive proxy materials for its proposed merger with Mount Logan Capital Inc. ("Mount Logan") in an all-stock transaction (the "Business Combination") after the market closed on Friday, July 11, 2025. The Board of Directors of 180 Degree Capital (the "Board") has set the date of the Special Meeting for the approval of the Business Combination (the "Business Combination Special Meeting") as August 22, 2025. The Board has set the record date for the Business Combination Special Meeting as July 8, 2025. The mailing of materials for the Business Combination Special Meeting is expected to begin on or about July 14, 2025.
Kevin Rendino and Daniel Wolfe will also host a shareholder call at 1pm ET on Tuesday, July 15, 2025, to discuss 180 Degree Capital's preliminary Q2 2025 results, and will be joined by Ted Goldthorpe, Chief Executive Officer of Mount Logan, to discuss the proposed Business Combination.

TURN

180 Degree Capital Notes Filing Of Definitive Materials For Proposed Business Combination With Mount Logan Capital; Co To Host Shareholder Call On July 15, 2025, At 1 PM ET

Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced an open letter to shareholders from CEO John Belizaire.
A longer version of the letter and updated investor presentation can be found on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fsolunacomputing.com%2Finvestors%2Fupdates&amp;esheet=54289724&amp;newsitemid=20250714846716&amp;lan=en-US&amp;anchor=Soluna%26%238217%3Bs+Investor+Relations&amp;index=1&amp;md5=348fcf14e4a49898046b8c71e364d8a8">Soluna's Investor Relations</a> webpage. Additionally, we will release an update to our Earnings Power Presentation in the coming weeks.
Soluna's annual shareholder meeting is scheduled for August 18, 2025 at 10:00am EDT.
Open Letter to Shareholders from John Belizaire, CEO of Soluna Holdings, Inc.
Dear Shareholders,
2024 was a defining year for Soluna. We grew revenue by more than 80%, reached $38 million, and achieved positive cash flow from our Bitcoin Hosting business — proof that our model is working.
We brought Project Dorothy 1A and 1B into full-year operation and launched our Demand Response Services (DRS), generating $2.1 million in new revenue. Project Dorothy 2, a 64% hosting capacity expansion, is now energized and is expected to reach 48 MW by year-end.
We simplified our capital structure, secured flexible funding through a $25 million SEPA facility, and made the strategic decision to exit the HPE contract, redeploying resources toward dedicated AI and HPC infrastructure, which is in high demand and where we have a clear advantage.
With the addition of Project Annie (75 MW), our first solar-powered site, Soluna's development pipeline now exceeds 773 MW across wind, grid, and solar-powered computing projects. Project Kati (166 MW) is shovel-ready, with Project Rosa (187 MW), Project Hedy (120 MW), and Project Ellen (100 MW) in active development. Soluna is no longer just proving its concept — we're scaling it.
Looking Ahead: Building the Future of Renewable Computing
In 2025, we plan to:
<ul>
<li>Ramp Project Dorothy 2 to full capacity and increase recurring revenue from Bitcoin Hosting.</li>
<li>Break ground on Project Kati, a flagship site for hybrid Bitcoin and AI workloads.</li>
<li>Advance Project Rosa, a 187 MW site designed for large-scale computing.</li>
<li>Expand and de-risk our pipeline, now exceeding 2.8 GW of AI and Bitcoin hosting capacity.</li>
<li>Form new joint ventures to deploy capital efficiently and enter the AI infrastructure market with industry leaders.</li>
<li>Strengthen our balance sheet, reduce debt, and own larger stakes in high-performing projects.</li>
</ul>
We are building more than data centers. We are laying the foundation for the future of computing. Our ability to turn curtailed renewable energy into reliable, low-cost power for Bitcoin and AI workloads sets us apart.
Soluna is positioned to lead this next era of energy and computing. We look forward to accelerating our growth, deepening our impact, and delivering strong returns for our shareholders.
Thank you for your continued belief in our mission.
Warm regards,
John Belizaire Chief Executive Officer

SLNH

Soluna CEO Touts 80% Revenue Jump, Plans Big Bitcoin and AI Growth With Solar-Powered Data Centers

Keefe, Bruyette &amp; Woods analyst Michael Brown downgrades Perella Weinberg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>) from Outperform to Market Perform and raises the price target from $22 to $23.

Downgrades

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

Keefe, Bruyette & Woods Downgrades Perella Weinberg to Market Perform, Raises Price Target to $23

WIIM

BITF

CLSK

COIN

HIVE

MARA

MSTR

RIOT

Shares of crypto-linked stocks and Bitcoin miners are trading higher after Bitcoin rose above $121,000.

Alcoa And JV Partner, IGNIS Equity Holdings, To Resume Restart Process Of San Ciprián Smelter In Spain

JP Morgan analyst Andrew Steinerman reinstates Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Overweight and announces $239 price target.

CTAS

JP Morgan Reinstates Overweight on Cintas, Announces $239 Price Target

Arizona State University (ASU), one of the largest universities in the United States, is expanding its partnership with Aramark, adding that company's expertise in other industries to the collegiate hospitality services it currently provides. This customized, comprehensive approach will deliver innovations in collegiate dining, high-end catering, sports facility concessions and club services, and vending to the 18-year relationship with the university, repeatedly ranked as the No. 1 "Most Innovative School" by US News &amp; World Report.
 &nbsp;

ARMK

Arizona State University Expands Partnership With Aramark To Deliver Expertise Across Industries

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

DEFT

DeFi Technologies Announces Subsidiary Valour's Bitcoin AUM Reached $302M

Camping World, Inc. and FreedomRoads Holding Company, LLC, subsidiaries of Camping World Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>), won a total victory in the latest legal proceeding arising out of the unscripted television series on CNBC, The Profit. The case was brought by tiny home manufacturer and participants on The Profit,Tumbleweed Tiny Homes, and its CEO Steve Weissmann, who is personally liable to FreedomRoads for $4.1M in damages, and to Camping World, FreedomRoads, and Marcus Lemonis for nearly $4.5M in attorneys' fees and costs.
Arbitrator Hon. Candace Cooper (Ret.) found Tumbleweed and Weissmann liable for their failure to pay back loans they took from FreedomRoads, which allowed Tumbleweed and Weissmann to keep their business open. Justice Cooper rejected every one of Tumbleweed and Weissmann's baseless allegations of misconduct, finding that the "weight of the evidence shows that Lemonis was attempting to ‘save' Tumbleweed, not have it fail . . ." Justice Cooper awarded Camping World, FreedomRoads, and Lemonis nearly $4.5M in attorneys' fees and costs and awarded another $5M in attorneys' fees and costs in favor of two other respondents, NBCUniversal and Machete Corporation. Judge Christopher Liu of the Los Angeles Superior Court confirmed Justice Cooper's award and entered judgment against Weissmann and Tumbleweed on July 8, 2025.
Following Justice Cooper's award, a recent public filing shows that Weissmann continued to accept customer orders for tiny homes and hundreds of thousands of dollars in customer deposits even though he knew Tumbleweed did not have the funds to keep operating the business. That filing shows that nearly a dozen customers trusted Weissmann with $250,000 in deposits on tiny home orders he never fulfilled, and as of recently, Weissmann had not paid his customers back.
In response to the award, Lemonis stated, "I hope this case is an example to people that there are consequences for pursuing false allegations. The truth matters. In this case, yet again, the truth won."
This is the second fully litigated case arising out of The Profit. In the first (brought by the Estate of Precise Graphix), Arbitrator Hon. Ann I. Jones (Ret.) found "Marcus Lemonis, at all times, acted in good faith with regard to Precise Graphix" and awarded over $7 million to the defendants, including Lemonis and Camping World. Two other similar cases arising out of the show and brought by Fox met similar fates. In one, a New York state court sanctioned Fox and awarded his clients nothing. In another, in Illinois State Court, Fox voluntarily dismissed his clients' claims against Lemonis after threats of sanctions for pursuing frivolous claims.

Legal

Camping World Wins $9M Legal Battle Over CNBC's The Profit, CEO of Tiny Home Company Held Liable

Keefe, Bruyette &amp; Woods analyst Paul Johnson initiates coverage on Blue Owl Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTF#NYSE">OTF</a>) with a Market Perform rating and announces Price Target of $16.

Keefe, Bruyette & Woods Initiates Coverage On Blue Owl Technology with Market Perform Rating, Announces Price Target of $16

Biotech

General

IOVA

Iovance Biotherapeutics Announces Real-World Study Demonstrating 49% Response Rate For Commercial Amtagvi In Patients With Advanced Melanoma

Cayson Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPN#NASDAQ">CAPN</a>) ("Cayson"), a special purpose acquisition company, and Mango Financial Limited ("Mango"), a full licensed boutique investment bank in Hong Kong, today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement"). Upon the closing of the transactions contemplated by the Merger Agreement, Cayson will become a wholly owned subsidiary of Mango Financial Group Limited ("Mango Group"), which will become the parent company of Mango, and the securities of the combined company are expected to be listed on Nasdaq.

CAPN

Cayson Acquisition And Mango Financial Ink Merger Agreement; Combined Entity To Trade On Nasdaq

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on ProMIS Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) with a Buy rating and announces Price Target of $4.

HC Wainwright & Co. Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $4

MGRM

Zimmer Biomet Says 'Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027'

Goldman Sachs analyst Alexander Duval initiates coverage on Nebius Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) with a Buy rating and announces Price Target of $68.

NBIS

Goldman Sachs Initiates Coverage On Nebius Group with Buy Rating, Announces Price Target of $68

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. The respective boards of directors of Zimmer Biomet and Monogram have unanimously approved the proposed transaction.

Zimmer Biomet To Acquire Monogram Technologies For $4.04/Share; Monogram Shareholders To Also Receive CVR Entitling Holder To Receive Up To $12.37/Share OF Stock In Cash If Certain Milestones Are Achieved Through 2030

JP Morgan analyst Bill Peterson reinstates Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Neutral and announces $7.5 price target.

JP Morgan Reinstates Neutral on Cleveland-Cliffs, Announces $7.5 Price Target

DeFi Development Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) stock gained on Monday after it issued its first <a target="_blank" href="https://www.benzinga.com/topic/solana" rel="noreferrer noopener">forward-looking guidance</a> on Solana&nbsp;(CRYPTO: SOL/USD) per Share (SPS), the company&#8217;s primary performance metric.
DeFi Development outlined a medium-term objective of reaching 1.0 SPS by December 2028 and near-term guidance of 0.1650 SPS by June 2026, representing approximately 261% growth from Monday&#8217;s level of 0.0457.
As part of its ongoing accumulation strategy, the company also announced it had purchased an additional 10,758 SOL at an average price of $161.30.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45217853/exclusive-defi-development-corp-expands-digital-asset-portfolio-holds-58-5-million-in-solana-tokens" rel="noreferrer noopener">DeFi Development Corp Expands Digital Asset Portfolio, Holds $58.5 Million In Solana Tokens</a>
On May 12, DeFi Development announced <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45344230/exclusive-defi-development-makes-record-solana-purchase-surpasses-100-million-in-treasury-holdings" rel="noreferrer noopener">it had purchased</a> 172,670 SOL at an average purchase price of $136.81, valued at&nbsp;approximately $23.6 million.
This marks the company&#8217;s tenth Solana purchase under its digital asset treasury strategy and its largest purchase. DeFi Development held 595,988 SOL, valued at approximately $102.7 million then.
As of May 12, DeFi Development had 2.04 million total outstanding shares. The SPS was 0.293, or $50.42.
Price Action: DFDV stock traded higher by 3.49% to $28.20 premarket at the last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46373610/amc-stock-just-got-upgrade-could-premium-screens-box-office-momentum-signal-a-comeback" target="_blank" rel="noreferrer noopener">AMC Stock Just Got Upgrade — Could Premium Screens, Box Office Momentum Signal A Comeback?</a></li>
</ul>
Photo by Lee Wa Da via Shutterstock

Guidance

Exclusives

DFDV

EXCLUSIVE: DeFi Development Issues First Outlook, Targets 1.0 SPS By 2028

Press Releases

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Comments

Genmab

Notizie

Ultime notizie per Genmab (NASDAQ:GMAB) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO